Enhancing Cancer Therapy Precision: Patient-derived organoids to interrogate phenotypic transitions in metastatic cancer and for high throughput therapeutic screening
Metastasis involves non-genetic phenotypic plasticity, leading to therapy resistance and poor clinical outcomes. Dr. Karuna Ganesh will cover the use of single cell transcriptomics and organoid modeling of patient-derived normal colon, primary and metastatic colorectal cancer, defining conserved phenotypic transitions and underlying mechanisms, identifying opportunities to target plasticity to treat advanced cancer.
Advances in cancer research using 3D organoid models for high throughput screening (HTS) bridge in vitro and in vivo studies, enhancing personalized medicine. Dr. Fernandez Vega will discuss therapeutic screening of diverse 3D patient-derived tumor organoids in miniaturized 1536-format against thousands of compounds in a rapid, automated, and cost-effective platform.
Presented by:
